US pharma giant buys Germany's Celesio in $8-bn deal

US pharmaceutical distributor McKesson on Thursday announced the purchase of German rival Celesio in a deal valued at more than $8 billion.

The combined company "will be one of the largest pharmaceutical wholesalers and providers of logistics and services in the worldwide," the German firm said in a statement.

The total transaction, including McKesson's takeover of Celesio's outstanding debt is valued at approximately $8.3 billion (6.3 billion euros, the statement added.

Both firms will keep their own separate brands.

The combined firm is expected to have annual revenue of more than $150 billion, employing some 81,500 people in 20 countries worldwide.

Earlier in the month, shares in McKesson rose sharply after the Wall Street Journal reported news of the buy-out.

add to favorites email to friend print save as pdf

Related Stories

Israeli generic drug giant Teva to buy Cephalon

May 02, 2011

Teva Pharmaceutical Industries, the world's largest generic drug maker, will buy US biopharma firm Cephalon in a $6.8 billion deal, the companies said in a joint statement Monday.

US chemists Walgreens spends $6.7 bn on 45% of Boots

Jun 19, 2012

US-based Walgreens said on Tuesday was spending $6.7 billion (£4.3 billion, 5.3 billion euros) to take a 45-percent stake in European rival Alliance Boots to create the world's largest retail pharmacy chain.

German software giant SAP unveils solid Q2 profits

Jul 12, 2012

Shares in German software giant SAP soared on Thursday as it announced what it hailed as its "best-ever second quarter performance", beating analysts' expectations for operating profits.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

User comments